key: cord-0292129-3lxyianh
authors: Alharbi, N. K.; Al-Tawfiq, J. A.; Alghnam, S.; Alwehaibe, A.; Alasmari, A.; Alsagaby, S. A.; Alotaibi, F.; Alsubaie, F.; Alshomrani, M.; Farahat, F. M.; Bosaeed, M.; Alharbi, A.; Aldibasi, O.; Assiri, A.
title: Effectiveness of COVID-19 Vaccines: Eight Months Post Single Dose Vaccination
date: 2021-09-22
journal: nan
DOI: 10.1101/2021.09.18.21263262
sha: 06315f99259e34464d952602385cf623b7ceedd4
doc_id: 292129
cord_uid: 3lxyianh

Objectives: To describe the real-world data on the effectiveness of Pfizer-BioNtech BNT162b2 and AstraZeneca-Oxford AZD1222 vaccines against COVID-19 in a large cohort in the Kingdom of Saudi Arabia (KSA). Methods: A total of 18,543 subjects received a single-dose of either of the vaccines at one vaccination centre in KSA, and were followed up for three to eight months. Clinical data from medical records, adverse events (AEs) from a self-reporting system, and COVID-19 infection data from the national databases were retrieved and analysed. Results: Subjects median age was 33 years old with an average of 27.3 body mass index and the majority were male (60.1%). 92.17% of the subjects had no COVID-19 infection post-vaccination. Diabetes mellitus (p=0.0325), organ transplantation (p=0.0254), and morbid obesity (p=0.0014) were risk factors for infection post-vaccination. Unlike vaccine type, being Saudi, male, or obese was more likely to get the infection earlier. AE reports from 1084 subjects included injection site pain, fatigue, fever, myalgia, headache. Conclusion: Single-dose COVID-19 vaccines in KSA showed an effectiveness rate of 92.17% up to eight months follow-up. The rate for AZD1222 was higher than what have been previously reported. Side effects and AEs were within what has been reported in clinical trials.

A novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged in Wuhan, China in 2019 and spread globally (1) . The disease is known as coronavirus infectious disease 2019 (COVID-19) (2) . In March 2020, the World Health Organization (WHO), declared COVID-19 as a global pandemic and a public health emergency of international concern (3). SARS-CoV-2 is highly contagious and transmitted through human-to-human contact (3) . Most COVID-19 cases (81%) are asymptomatic or present with mild to moderate symptoms (4) . However, other cases are severe (14%) to critical pneumonia (5%); with a fatality rate of 2-3% (4). As of 5 th of September 2021, more than 222 million confirmed cases of COVID-19 and 4.5 million deaths were reported globally (5) . To reduce the risk of SARS-CoV-2 transmission, preventive strategies have been implemented, including the use of face masks, hand washing/hygiene, contact tracing, travel bans, and government-led cancellation of unnecessary activities (6) .

Importantly, prophylactic vaccines are sought as the ultimate intervention to bring the pandemic under control. Over 200 vaccine candidates for COVID-19 were at various stages of clinical development (7) . Of these, at least 50 candidate vaccines made it into human trials. To date, several vaccines have been approved by regulatory authorities, based on clinical trials that demonstrated a high safety profile and variable efficacy rates (7) . The results of phase III clinical trials showed 95% efficacy for the Pfizer-BioNtech BNT162b2 vaccine, 92% for the Gamaleya SputnikV vaccine, 94.5% for Moderna mRNA-1273 vaccine, 70% for the AstraZeneca-Oxford AZD1222 vaccine, and 97% for Sinopharm BIBP COVID-19 vaccine (7) (8) (9) .

Several different vaccine technologies have been used to develop the COVID-19 vaccines (10), including mRNA (11, 12) , adenoviral vectored vaccines (13, 14) , inactivated virus (15) , and adjuvanted spike glycoprotein (16) . The BNT162b2 vaccine is based on the lipid nanoparticleencapsulated nucleoside-modified messenger RNA (mRNA) that encodes the SARS-CoV-2 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 22, 2021. ;  https://doi.org/10.1101/2021.09.18.21263262 doi: medRxiv preprint spike (S) glycoprotein (17) , while the AZD1222 vaccine is based on the ChAdOx1 adenoviral vector encoding the SARS-CoV-2 spike (S) glycoprotein (10) . The Kingdom of Saudi Arabia (KSA) was among the first countries to launch an accelerated program for COVID-19

vaccination (18) . The approved COVID-19 vaccines that are being used in KSA are the Pfizer-BioNtech BNT162b2 vaccine, Moderna mRNA-1273 vaccine , and AstraZeneca-Oxford AZD1222 vaccine (19) .

For each vaccine candidate, there were a number of vaccine controlled randomised clinical trials focusing on evaluating safety, immunogenicity, and efficacy (7, 20) , which were the basis for regulatory approvals. However, to gain a better understanding of how COVID-19 vaccines would perform in various populations, it is essential to gather real-world data and analysis postvaccination, in particular concerning different ethnic populations, in order to establish the longterm effectiveness (protection rate) in several different sub-populations. These subpopulations can be defined based on differences in gender, age, nationality, occupation, comorbidities and chronic disease (including haemodialysis and oncology patients).

Therefore, this study was conducted to evaluate the long-term effectiveness (protection rate) of Pfizer-BioNtech BNT162b2 and AstraZeneca-Oxford AZD1222 COVID-19 vaccines in KSA, including national and expatriate subjects from different countries. It also looks at the demographics and clinical characteristics of subjects and the adverse events (AE) postvaccination.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

In this study, data for 20555 vaccinated subjects were collected from a single vaccination centre at National Guard Health Affairs (NGHA) hospitals in Riyadh city, Saudi Arabia. The subjects received either BNT162b2 or AZD1222 vaccines. Clinical data for all subjects were retrieved from the MNG-HA medical records. Confirmation of COVID-19 infections were obtained from the national database at the Ministry of Health which covers any COVID-19 PCR testing performed in the country. Subjects were given access to an online portal for reporting symptoms and adverse events; in addition, vaccine safety records at the Infection Prevention and Control Department at the King Abdulaziz Medical City (KAMC), MNG-HA, were interrogated. Side effects reports were obtained for around 6% of the vaccinated subjects. Those who were infected prior to vaccination, had two doses of Pfizer vaccine (who were less than 100 subjects), had the COVID-19 infection within two weeks of vaccination, or lack data on COVID-19 testing were excluded from the analysis presented in this article. Therefore, 18543 out of 20555 subjects were included in the study analysis.

Descriptive statistics were applied to summarise the data of subjects' demographical and clinical characteristics and the number of adverse events. Comparison between the two study groups preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.18.21263262 doi: medRxiv preprint odds ratios and 95% confidence intervals. Using the Wilcoxon rank-sum test, we test the number of days between vaccination and infection for infected individuals in terms of gender, nationality, and comorbidities. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC) and data visualisation using GraphPad Prism V8 software (GraphPad Software, San Diego, CA).

The study was approved by the IRB at KAIMRC for projects RC20/180 and NRC21R-120-03. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Vaccinated subjects who have no documented COVID-19 infection prior to vaccination were analysed in order to provide real-world data on COVID-19 vaccine effectiveness in this cohort.

Subjects were followed up for at least three months (last vaccination was on the 14 th April and last follow up was on the 10 th August). Out of 18543, 17091 (92.17%) remained uninfected postvaccination while the infection was documented for 1452 (7.83%) of the vaccinated individuals, Table 1 . Forty-six (11.2% of those who received BNT162b2) and 1406 (7.75% from those who received AZD1222) had the infection post two weeks of the single dose vaccination, indicating All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.18.21263262 doi: medRxiv preprint the effectiveness of these vaccines, Table S1 . Age does not appear to vary significantly in the two groups of vaccinated subjects (uninfected and infected); median age was 33 (IQR: 26 -43) for the uninfected group and 33 (IQR: 26 - Table 2 ). Infections that occur within two weeks of vaccination were only 73 cases and were not included in the study analysis. The data showed that the time between vaccination and infection (excluding the 73 cases) was between 14 and 146 days (median = 82 days), Figure 1 .

These periods of time were not different when broken by vaccine type (data as per vaccine type is not shown) and COVID-19 cases following the BNT162b2 vaccine were only 46, which does not allow a powerful statistical conclusion on this regard. In addition, these times were not different with regard to subject comorbidities (Table S2 ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

To provide insights on the adverse events (AE) to the vaccines in the study subjects, only 1084 subjects utilised the online reporting portal or contacted NGHA hospitals to report AE (Table 3) .

Although around 5.1% of the vaccinated subjects reported AE, lack of reporting does not ensure lack of side effects. Injection site pain was the most frequently reported AE (800 cases). Other common AEs include fatigue (732 cases), fever (714 cases), myalgia (678), headache (657 cases), joint pain and malaise (399 cases). In contrast, AEs, such as skin rash, cough, abdominal pain and tachycardia were only reported by single individuals among vaccinated subject.

All rights reserved. No reuse allowed without permission.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (8) . On the other hand, clinical trials showed an efficacy of 70% (95% CI: 55-81%) after two doses of the AZD1222 vaccine (8) . Data from real-world vaccination showed that two doses of BNT162b2 vaccine reduced the risk of SARS-CoV-2 infection by 90% (22) . In addition, it was found that most breakthrough infections were either asymptomatic or mildly symptomatic (23) .

In the current study, infection post vaccination were significantly higher in subjects with diabetes mellites, obesity, or organ transplantation. In a previous study, the rate of breakthrough infections was not different among vaccinees by age group, gender, or type of vaccine but were lower among those without comorbidities (0.44 [95% CI 0.25,0.62]) compared with those with 1 to 3 comorbidities (24). The contribution of underlying disease to breakthrough infections is of particular importance as additional boosting doses might be required. In one study, the immune responses after COVID-19 vaccine was lower among males and those with underlying All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101/2021.09.18.21263262 doi: medRxiv preprint comorbidities such as diabetes mellitus, hypertension and renal disease (25) . A meta-analysis showed that diabetic patients had increased risk for severe COVID-19 and increased mortality (26) . A multivariate logistic regression analysis on infection post-vaccination in the current study showed that Saudi, male, and obese subjects were more likely to contract COVID-19 post a single dose of COVID-19 vaccines. The reason for Saudi male to have higher rate of breakthrough infections might be related to the social norms, occupations, and behavioural interactions, warranting further social-epidemiological studies. The contribution of different ethnicity to the development of breakthrough infection was also reported previously (24, 27, 28) .

The percentage of the infected patients in our study would be affected by the endemicity of the virus in the study areas. Additionally, the pandemic has shown frequent waves and variations in the numbers of the daily new cases of COVID-19, which would certainly influence our findings.

Emerging variants of the SARS-CoV-2 might have an impact on the vaccine effectiveness, especially for the one dose protection, a strategy that has been followed by several countries due to vaccine logistic issues and the need to expand vaccination coverage in populations.

Therefore, long-term follow-up on the vaccinees is needed to estimate the longevity of the single-dose vaccine effect and effectiveness.

Of the 20555 vaccinated subjects, 1084 (5.1%) had utilised the online portal or contacted the hospital to report AEs following the vaccination. In an earlier study on vaccine safety and reactogenicity from KSA, 34.7% reported an adverse event on the first call after the vaccination (21) . These differences in the rate of AEs are likely related to the methodology of the two studies. The current study utilised self-reporting and the previous study utilised an active methodology by calling subjects to record any AEs. In the current study, the most reported AEs All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were injection site pain (n= 800), fatigue (n=732), fever (n=714), myalgia (n=678) and headache (n=657). The previously cited study from KSA also found that local AEs at the injection site were most common after AZD1222 (30.5%) (21) while the current study cannot establish a rate for this AE due to the used method. In a phase III clinical trial, injection-site pain was reported by 48.6% (29) ; however, this rate of occurrence varied for different vaccines (30) .

Fever was the most frequently reported adverse effects after COVID-19 vaccination in this study. Two previous studies from KSA reported fever in 18.5% after the first dose of BNT162b2 vaccine, 1.3% after the second dose and an overall rate of 4.3% (31) . The second study reported a rate of 31% after the AZD1222 vaccine (21) . In a third study from KSA, fever was reported in 66% of the subjects who received either AZD1222 or BNT162b2 vaccine (32) while fever was reported in 22% of participants receiving BNT162b2 vaccine in a randomisedcontrolled trial (33). The current study showed that 7 vaccinees had lymphadenopathy after COVID-19 vaccination. The incidence of ipsilateral axillary reactive lymphadenopathy following mRNA vaccine was 13% among 68 patients who had CT-scan (34). In addition, 20 vaccinees developed ipsilateral supraclavicular lymphadenopathy in a separate study (35). The estimated occurrence of lymphadenopathy was 1% and 10% after the after BNT162b2 and mRNA-1273 vaccines, respectively (36,37). Nevertheless, lymphadenopathy is usually documented following other intramuscular vaccines such as influenza and human papillomavirus vaccines (38,39).

In conclusion, this study is the first to investigate the safety and efficacy of two main vaccines in a large cohort in Saudi Arabia including national and expatriate subjects from different countries.

Single-dose COVID-19 vaccines showed an effectiveness rate of 92% with no major side effects during the three to eight months observational period. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. T r a n s p l a n t All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses

COVID-19 in early 2021: current status and looking forward

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19) Dashboard

SARS-CoV-2 and the pandemic of COVID-19

Looking beyond COVID-19 vaccine phase 3 trials

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Phase 1-2 Trial of a SARS

Recombinant Spike Protein Nanoparticle Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Launching COVID-19 vaccination in Saudi Arabia: Lessons learned, and the way forward

Interim guidelines for the use of SARS-CoV-2 vaccine Riyadh, Saudi Arabia Public Health Authority

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight U.S. Locations

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies

COVID-19 disparity among racial and ethnic minorities in the US: A cross sectional analysis

Prevalence and fatality rates of COVID-19: What are the reasons for the wide variations worldwide

Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ vaccines

Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study

Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia

The authors are grateful for the assistance of the COVID-19 vaccination center at MNG-HA and the Saudi Ministry of Health.

This study was funded by KAIMRC under the grant RC20/180; PI: Naif K. Alharbi.

The authors declare no conflict of interest. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.